Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
89.12 CHF | +0.29% | +0.13% | +4.94% |
Apr. 29 | Novartis target Morphosys multiplies losses - takeover schedule stands | DP |
Apr. 29 | Morphosys says takeover by Novartis on course after report of drug safety concern | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.94% | 199B | |
+26.47% | 664B | |
+30.25% | 567B | |
-6.33% | 354B | |
+19.35% | 330B | |
+4.23% | 286B | |
+14.28% | 234B | |
-10.06% | 196B | |
-4.04% | 148B | |
-10.94% | 145B |
- Stock Market
- Equities
- NOVN Stock
- News Novartis AG
- Novartis' Multiple Sclerosis Drug Shows Sustained Efficacy for Up to Six Years